Q4-FY26 · Satish Mata
We crossed a major milestone this year, surpassing $1 billion in revenue and having a growth of 16.6% year-on-year increase, exceeding the guidance row that we had given to you.
EMCUREPHARMACEUTICALS / language trends
Read confidence between the lines.
Emcure Pharmaceuticals · tone and specificity signals across the available quarters.
Research layer active
Language signals
What changed in management language.
tracked
Q4-FY26 · Satish Mata
Our adjusted PAT grew more than 40%, I repeat, our adjusted PAT grew more than 40%.
Q4-FY26 · Satish Mata
FY27 we project low to mid-teen revenue growth and as I have been explaining... margin expansion will happen as committed between 75 to 100 basis points going forward assuming stable regulations and macroeconomic conditions.